A Role of Thyroid Hormones in Acute Myocardial Infarction: An Update

Article ID: e280422204209 Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

The acute coronary syndrome is one of the commonest life-threatening illnesses. It encompasses the clinical spectrum of acute myocardial ischemia and includes unstable angina and acute myocardial infarction both with and without ST segment elevation. The acute coronary syndrome can be attributed to a significant hemodynamic insult that leads to atherosclerosis of the epicardial coronary arteries. The main causative risk factors, such as obesity, smoking, and alcohol intake, increase the burden of acute coronary syndrome. Owing to an increase in the utilization of antioxidants, the antioxidant capacity decreases concerning the scavenging of lipid peroxides. Moreover, the thyroid hormones are important regulators of the expression of cardiac genes, and many of the cardiac manifestations of thyroid dysfunction are associated with alterations in triiodothyronine- mediated gene expression. Cardiovascular signs and symptoms of thyroid disease are among the most acute clinically relevant findings that occur in combination with both hypothyroidism and hyperthyroidism. By understanding the cellular mechanism of the action of thyroid hormones on the heart and cardiovascular system, it is possible to explain rhythm disturbances and alterations in cardiac output, blood pressure, cardiac contractility, and vascular resistance that result from thyroid dysfunction. Oxidative stress is thereby induced, together with a decrease in antioxidant capacity for overcoming oxidative stress, which leads to endothelial dysfunction, subsequent atherosclerosis, and, ultimately, acute myocardial infarction. The implications for the identification of the effects of thyroid disease on acute myocardial infarction include the observation that restoration of normal thyroid function repeatedly reverses abnormalities in cardiovascular hemodynamics.

Keywords: Cardiovascular, thyroid hormonE, hypothyroidism, hyperthyroidism, myocardial infarction, thyroid.

[1]
Sinha R, Yen PM. Cellular action of thyroid hormone 2015.
[2]
Organization WH. Global status report on noncommunicable diseases 2014. World Health Organization 2014.
[3]
Patel C, Burke JF, Patel H, et al. Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: A century of controversy. Circ Arrhythm Electrophysiol 2009; 2(1): 80-8.
[http://dx.doi.org/10.1161/CIRCEP.108.791830] [PMID: 19808446]
[4]
Herman PM, Walsh ME. Hospital admissions for acute myocardial infarction, angina, stroke, and asthma after implementation of Arizona’s comprehensive statewide smoking ban. Am J Public Health 2011; 101(3): 491-6.
[http://dx.doi.org/10.2105/AJPH.2009.179572] [PMID: 20466955]
[5]
Brown DA, O’Rourke B. Cardiac mitochondria and arrhythmias. Cardiovasc Res 2010; 88(2): 241-9.
[http://dx.doi.org/10.1093/cvr/cvq231] [PMID: 20621924]
[6]
Ahmad W, Ibrahim MSM. High density lipoprotein cholesterol predicts triglycerides level in three distinct phases of blood pressure. Int J Sci Basic Appl Res 2013; 10(1): 38-46.
[7]
Jamil G, Jamil M, Alkhazraji H, et al. Risk factor assessment of young patients with acute myocardial infarction. Am J Cardiovasc Dis 2013; 3(3): 170-4.
[PMID: 23991352]
[8]
Egred M, Viswanathan G, Davis GK. Myocardial infarction in young adults. Postgrad Med J 2005; 81(962): 741-5.
[http://dx.doi.org/10.1136/pgmj.2004.027532] [PMID: 16344295]
[9]
Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: Epidemiology, risk factors, and treatments: A scientific statement from the American Heart Association. Circulation 2018; 138(1): e1-e34.
[http://dx.doi.org/10.1161/CIR.0000000000000580] [PMID: 29794080]
[10]
Wood DM, Hill D, Gunasekera A, Greene SL, Jones AL, Dargan PI. Is cocaine use recognised as a risk factor for acute coronary syndrome by doctors in the UK? Postgrad Med J 2007; 83(979): 325-8.
[http://dx.doi.org/10.1136/pgmj.2006.053850] [PMID: 17488862]
[11]
Stathatos N. Anatomy and physiology of the thyroid gland.The Thyroid and Its Diseases. Springer 2019; pp. 3-12.
[http://dx.doi.org/10.1007/978-3-319-72102-6_1]
[12]
Roth GA, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. 2018; 392(10159): 1736-88.
[13]
WHO. 2019.
[14]
Benjamin EJ, et al. Heart disease and stroke statistics—2019 update: A report from the American Heart Association. 2019; 139(10): e56-e528.
[15]
Klein I. Ojamaa KJNEJoM. Thyroid hormone and the cardiovascular system. 2001; 344(7): 501-9.
[http://dx.doi.org/10.1056/NEJM200102153440707]
[16]
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women. The Rotterdam Study 2000; 132(4): 270-8.
[http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00004]
[17]
Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14(1): 39-55.
[http://dx.doi.org/10.1038/nrcardio.2016.174] [PMID: 27811932]
[18]
Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid downregulation of thyroid hormones in acute myocardial infarction: Is it cardioprotective in patients with angina? 2002; 162(12): 1388-94.
[http://dx.doi.org/10.1001/archinte.162.12.1388]
[19]
Kumar E, McCurdy MT, Koch CA, Hamadah A, Fülöp T, Gharaibeh KA. Impairment of thyroid function in critically ill patients in the intensive care units. 2018; 355(3): 281-5.
[http://dx.doi.org/10.1016/j.amjms.2017.06.026]
[20]
Cerillo AG, Storti S, Clerico A, Iervasi G. Thyroid function and cardiac surgery: What should we measure, and when? 2010; 89(3): 1010-.
[http://dx.doi.org/10.1016/j.athoracsur.2009.08.046]
[21]
Kalofoutis C, Mourouzis I, Galanopoulos G, et al. Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. 2010; 345(1): 161-9.
[http://dx.doi.org/10.1007/s11010-010-0569-4]
[22]
Pingitore A, Chen Y, Gerdes AM, Iervasi G. Acute myocardial infarction and thyroid function: New pathophysiological and therapeutic perspectives. 2012; 44(8): 745-57.
[http://dx.doi.org/10.3109/07853890.2011.573501]
[23]
Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: A review. Thyroid 2002; 12(8): 683-702.
[http://dx.doi.org/10.1089/105072502760258668] [PMID: 12225637]
[24]
Dharmalingam M, Kaduskar PU. Toxic Nodular Goiter and Adenoma. Principles and Practices of Thyroid Gland Disorders 2017; p. 198.
[25]
Helfand M, Crapo LM. Screening for thyroid disease. Ann Intern Med 1990; 112(11): 840-9.
[http://dx.doi.org/10.7326/0003-4819-112-11-840] [PMID: 2111649]
[26]
Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism - a neglected thyroid disorder. Nat Rev Endocrinol 2017; 13(10): 588-98.
[http://dx.doi.org/10.1038/nrendo.2017.47] [PMID: 28549061]
[27]
Bernstein R, Müller C, Midtbø K, Smith G, Haug E, Hertzenberg L. Silent myocardial ischemia in hypothyroidism. Thyroid 1995; 5(6): 443-7.
[http://dx.doi.org/10.1089/thy.1995.5.443] [PMID: 8808093]
[28]
Kannan L, Shaw PA, Morley MP, et al. Thyroid dysfunction in heart failure and cardiovascular outcomes. Circ Heart Fail 2018; 11(12): e005266.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005266] [PMID: 30562095]
[29]
Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab 2005; 90(9): 5489-96.
[http://dx.doi.org/10.1210/jc.2005-0170] [PMID: 16148346]
[30]
Nakova VV, Krstevska B, Bosevski M, Dimitrovski Ch, Serafimoski V. Dyslipidaemia and hypertension in patients with subclinical hypothyroidism. Prilozi. Odd Biol Med Nauki 2009; 30(2): 93-102.
[31]
Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165(21): 2467-72.
[http://dx.doi.org/10.1001/archinte.165.21.2467] [PMID: 16314542]
[32]
Rodondi N, Newman AB, Vittinghoff E, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; 165(21): 2460-6.
[http://dx.doi.org/10.1001/archinte.165.21.2460] [PMID: 16314541]
[33]
Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am 1998; 27(1): 51-62.
[http://dx.doi.org/10.1016/S0889-8529(05)70297-8] [PMID: 9534027]
[34]
Ertek S, Cicero AF. Hyperthyroidism and cardiovascular complications: A narrative review on the basis of pathophysiology. Arch Med Sci 2013; 9(5): 944-52.
[http://dx.doi.org/10.5114/aoms.2013.38685] [PMID: 24273583]
[35]
Ojamaa K, Kenessey A, Shenoy R, Klein I. Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am J Physiol Endocrinol Metab 2000; 279(6): E1319-24.
[http://dx.doi.org/10.1152/ajpendo.2000.279.6.E1319] [PMID: 11093920]
[36]
Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994; 78(5): 1028-33.
[PMID: 8175955]
[37]
Bouzaffour M, Rampon C, Ramaugé M, Courtin F, Vriz S. Implication of type 3 deiodinase induction in zebrafish fin regeneration. Gen Comp Endocrinol 2010; 168(1): 88-94.
[http://dx.doi.org/10.1016/j.ygcen.2010.04.006] [PMID: 20403357]
[38]
Jopling C, Sleep E, Raya M, Martí M, Raya A, Izpisúa Belmonte JC. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 2010; 464(7288): 606-9.
[http://dx.doi.org/10.1038/nature08899] [PMID: 20336145]
[39]
Buss SJ, Riffel JH, Malekar P, et al. Chronic Akt blockade aggravates pathological hypertrophy and inhibits physiological hypertrophy. Am J Physiol Heart Circ Physiol 2012; 302(2): H420-30.
[http://dx.doi.org/10.1152/ajpheart.00211.2011] [PMID: 22058151]
[40]
Pantos C, Mourouzis I, Cokkinos DV. New insights into the role of thyroid hormone in cardiac remodeling: Time to reconsider? Heart Fail Rev 2011; 16(1): 79-96.
[http://dx.doi.org/10.1007/s10741-010-9185-3] [PMID: 20668933]
[41]
Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D. Thyroid hormone and “cardiac metamorphosis”: Potential therapeutic implications. Pharmacol Ther 2008; 118(2): 277-94.
[http://dx.doi.org/10.1016/j.pharmthera.2008.02.011] [PMID: 18455802]
[42]
Forini F, Lionetti V, Ardehali H, et al. Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats. J Cell Mol Med 2011; 15(3): 514-24.
[http://dx.doi.org/10.1111/j.1582-4934.2010.01014.x] [PMID: 20100314]
[43]
Abohashem-Aly AA, Meng X, Li J, et al. DITPA, a thyroid hormone analog, reduces infarct size and attenuates the inflammatory response following myocardial ischemia. J Surg Res 2011; 171(2): 379-85.
[http://dx.doi.org/10.1016/j.jss.2011.04.009] [PMID: 21658725]
[44]
Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007; 49(5): 962-70.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.106.079426] [PMID: 17389260]
[45]
Coghlan C, Hoffman J. Leonardo da Vinci’s flights of the mind must continue: Cardiac architecture and the fundamental relation of form and function revisited. Eur J Cardiothorac Surg 2006; 29 (Suppl. 1): S4-S17.
[http://dx.doi.org/10.1016/j.ejcts.2006.03.010] [PMID: 16564694]
[46]
Sehgal S, Drazner MH. Left ventricular geometry: Does shape matter? Am Heart J 2007; 153(2): 153-5.
[http://dx.doi.org/10.1016/j.ahj.2006.10.026] [PMID: 17239670]
[47]
Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23(1): 38-89.
[http://dx.doi.org/10.1210/edrv.23.1.0455] [PMID: 11844744]
[48]
Everts ME. Effects of thyroid hormones on contractility and cation transport in skeletal muscle. Acta Physiol Scand 1996; 156(3): 325-33.
[http://dx.doi.org/10.1046/j.1365-201X.1996.203000.x] [PMID: 8729693]
[49]
Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005; 26(5): 704-28.
[http://dx.doi.org/10.1210/er.2003-0033] [PMID: 15632316]
[50]
Watanabe M, Kakuta H. Retinoid X receptor antagonists. Int J Mol Sci 2018; 19(8): 2354.
[http://dx.doi.org/10.3390/ijms19082354] [PMID: 30103423]
[51]
Klein I, Danzi S. Thyroid disease and the heart. Curr Probl Cardiol 2016; 41(2): 65-92.
[http://dx.doi.org/10.1016/j.cpcardiol.2015.04.002] [PMID: 26792255]
[52]
Vargas F, Moreno JM, Rodríguez-Gómez I, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006; 154(2): 197-212.
[http://dx.doi.org/10.1530/eje.1.02093] [PMID: 16452532]
[53]
Kuzman JA, Gerdes AM, Kobayashi S, Liang Q. Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005; 39(5): 841-4.
[http://dx.doi.org/10.1016/j.yjmcc.2005.07.019] [PMID: 16171808]
[54]
Hiroi Y, Kim HH, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006; 103(38): 14104-9.
[http://dx.doi.org/10.1073/pnas.0601600103] [PMID: 16966610]
[55]
Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003; 88(8): 3731-7.
[http://dx.doi.org/10.1210/jc.2003-030039] [PMID: 12915662]
[56]
Danzi S, Klein I, Portman MA. Effect of triiodothyronine on gene transcription during cardiopulmonary bypass in infants with ventricular septal defect. Am J Cardiol 2005; 95(6): 787-9.
[http://dx.doi.org/10.1016/j.amjcard.2004.11.039] [PMID: 15757614]
[57]
Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: Response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002; 87(4): 1533-8.
[http://dx.doi.org/10.1210/jcem.87.4.8378] [PMID: 11932277]
[58]
Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: Randomized, crossover trial. J Clin Endocrinol Metab 2007; 92(5): 1715-23.
[http://dx.doi.org/10.1210/jc.2006-1869] [PMID: 17299073]
[59]
Rush J, Danzi S, Klein I. Role of thyroid disease in the development of statin-induced myopathy. Endocrinologist 2006; 16(5): 279-85.
[http://dx.doi.org/10.1097/01.ten.0000240960.40281.2b]
[60]
Donepudi AC, Ferrell JM, Boehme S, Choi HS, Chiang JYL. Deficiency of cholesterol 7α-hydroxylase in bile acid synthesis exacerbates alcohol-induced liver injury in mice. Hepatol Commun 2017; 2(1): 99-112.
[http://dx.doi.org/10.1002/hep4.1129] [PMID: 29404516]
[61]
Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116(15): 1725-35.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.678326] [PMID: 17923583]
[62]
Choi Y-H, Chung JH, Bae SW, et al. Severe coronary artery spasm can be associated with hyperthyroidism. Coron Artery Dis 2005; 16(3): 135-9.
[http://dx.doi.org/10.1097/00019501-200505000-00001] [PMID: 15818081]
[63]
Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: A matched case-control study. J Am Coll Cardiol 2007; 49(1): 71-81.
[http://dx.doi.org/10.1016/j.jacc.2006.08.042] [PMID: 17207725]
[64]
Stanciu AE, et al. The role of the clinical cardiac electrophysiologist in the management of congestive heart failure.Impact of Thyroid Disease on Heart Failure. 2017; p. 141.
[http://dx.doi.org/10.5772/66283]
[65]
Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the Heart. Methodist DeBakey Cardiovasc J 2017; 13(2): 55-9.
[http://dx.doi.org/10.14797/mdcj-13-2-55] [PMID: 28740582]
[66]
Hardaway AL, Podgorski I. IL-1β RAGE and FABP4: Targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem 2013; 5(10): 1089-108.
[http://dx.doi.org/10.4155/fmc.13.90] [PMID: 23795967]
[67]
Nibbs RJ, Graham GJ. Immune regulation by atypical chemokine receptors. Nat Rev Immunol 2013; 13(11): 815-29.
[http://dx.doi.org/10.1038/nri3544] [PMID: 24319779]
[68]
Beaulieu LM, Lin E, Mick E, et al. Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol 2014; 34(3): 552-64.
[http://dx.doi.org/10.1161/ATVBAHA.113.302700] [PMID: 24458711]
[69]
Al-Ghoul WM, Kim MS, Fazal N, Azim AC, Ali A. Evidence for simvastatin anti-inflammatory actions based on quantitative analyses of NETosis and other inflammation/oxidation markers. Results Immunol 2014; 4: 14-22.
[http://dx.doi.org/10.1016/j.rinim.2014.03.001] [PMID: 24809006]
[70]
Zhang L, Peppel K, Sivashanmugam P, et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27(5): 1087-94.
[http://dx.doi.org/10.1161/01.ATV.0000261548.49790.63] [PMID: 17442899]
[71]
Kornman KS. Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am J Clin Nutr 2006; 83(2): 475S-83S.
[http://dx.doi.org/10.1093/ajcn/83.2.475S] [PMID: 16470016]
[72]
Dalle-Donne I, Scaloni A, Giustarini D, et al. Proteins as biomarkers of oxidative/nitrosative stress in diseases: The contribution of redox proteomics. Mass Spectrom Rev 2005; 24(1): 55-99.
[http://dx.doi.org/10.1002/mas.20006] [PMID: 15389864]
[73]
Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol 2013; 1(1): 483-91.
[http://dx.doi.org/10.1016/j.redox.2013.07.006] [PMID: 24251116]
[74]
Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: What’s new in the management arena? Vasc Health Risk Manag 2010; 6: 665-9.
[http://dx.doi.org/10.2147/VHRM.S5686] [PMID: 20859538]
[75]
Ho E, Galougahi KK, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol 2013; 1: 483-91.
[76]
Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena? Vasc Health Risk Manag 2010; 6: 665.